{"id":398020,"date":"2020-12-11T01:03:21","date_gmt":"2020-12-11T06:03:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=398020"},"modified":"2020-12-11T01:03:21","modified_gmt":"2020-12-11T06:03:21","slug":"innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/","title":{"rendered":"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Innate<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>will <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>no longer<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em> pursue Lumoxiti <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>commercialization <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>activities <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>in US or E<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>U<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>; <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>Company <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>to<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>re<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>-focus<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em> investments<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em> in<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>its <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>R&amp;D p<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>ortfolio\u00a0<\/p>\n<p><\/em><br \/>\n          <\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Companies <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>will <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>develop<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>a<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>transition<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em> plan<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>with the goal of returning full commercialization <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>responsibilities<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em> to <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>AstraZeneca<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>in<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em> 2021<\/em><br \/>\n          <\/strong><\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>C<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>ompanies <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>will<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>ensure availability of Lumoxiti to patients <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>during transition period <\/em><br \/>\n          <\/strong><\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>C<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>onference call to be held <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>today<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>at <\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>2 pm CET<\/em><br \/>\n          <\/strong><br \/>\n          <strong><br \/>\n            <em>\/ 8 am ET<\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p>MARSEILLE, France, Dec.  11, 2020  (GLOBE NEWSWIRE) &#8212; Innate Pharma SA (Euronext Paris: IPH \u2013 ISIN: FR0010331421; Nasdaq: IPHA) (\u201c<strong>Innate<\/strong>\u201d or the \u201c<strong>Company<\/strong>\u201d) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca<sup>1<\/sup>. Innate licensed the US and EU rights to AstraZeneca\u2019s FDA-approved Lumoxiti for certain patients with relapsed or refractory hairy cell leukemia in <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j70fYHnUDom6SufZ4gp2zF9_-87CB2LBAlGV2sT-IXw-R6nXORkgUQsoSkbfDaSufRS3dbGUvA4b9Xr_jklGNemrcg3ilamOEl_D4lo5E5Q0-ownywRn7B1fX5rCLAwF_6X7LswL7OZ2GCYeUsPTeU5a-XO28sQ3Yl-JBj8rPLGCysb1LsaeLOBcOAL9VQEw197BNymSjzbQ5vTF0OtVIbVzTJXI7Llwz8JiQ8fWYArmmpG4TJ3XWdHBzdh-K-kk\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">October 2018<\/a>.<\/p>\n<p align=\"both\">The companies will develop a transition plan, including costs and transfer of the US marketing authorization and distribution of Lumoxiti back to AstraZeneca in 2021. AstraZeneca will remain the marketing authorization applicant for the EU filing.<\/p>\n<p align=\"both\">\n        <em>\u201cSince in-licensing Lumoxiti from AstraZeneca, we have been committed to delivering this medicine to patients and healthcare professionals in the US, and moving towards commercialization in the EU. <\/em><br \/>\n        <em>However,<\/em><br \/>\n        <em>we\u2019ve determined that there is low<\/em><br \/>\n        <em>strategic value <\/em><br \/>\n        <em>for us<\/em><br \/>\n        <em>in<\/em><br \/>\n        <em> main<\/em><br \/>\n        <em>taining<\/em><br \/>\n        <em> Lumoxiti in our portfolio<\/em><br \/>\n        <em> due to<\/em><br \/>\n        <em> lower than anticipated<\/em><br \/>\n        <em> product<\/em><br \/>\n        <em> sales<\/em><br \/>\n        <em>, <\/em><br \/>\n        <em>further compounded by the <\/em><br \/>\n        <em>ongoing <\/em><br \/>\n        <em>COVID-19 pandemic<\/em><br \/>\n        <em>. This<\/em><br \/>\n        <em> has<\/em><br \/>\n        <em> led <\/em><br \/>\n        <em>us to <\/em><br \/>\n        <em>ma<\/em><br \/>\n        <em>k<\/em><br \/>\n        <em>e the<\/em><br \/>\n        <em> decision to <\/em><br \/>\n        <em>re-<\/em><br \/>\n        <em>prioritize our investments in our R&amp;D portfolio,\u201d <\/em><br \/>\n        <strong>s<\/strong><br \/>\n        <strong>aid <\/strong><br \/>\n        <strong>Mondher Mahjoubi, Chief Executive Officer of Innate Pharma<\/strong><br \/>\n        <strong>.\u00a0<\/strong><br \/>\n        <em>\u201c<\/em><br \/>\n        <em>W<\/em><br \/>\n        <em>e will <\/em><br \/>\n        <em>continue to embed a commercial mindset into our R&amp;D programs, <\/em><br \/>\n        <em>which <\/em><br \/>\n        <em>is a key success factor <\/em><br \/>\n        <em>for<\/em><br \/>\n        <em> the development <\/em><br \/>\n        <em>and future commercialization <\/em><br \/>\n        <em>of our <\/em><br \/>\n        <em>pipeline <\/em><br \/>\n        <em>assets<\/em><br \/>\n        <em>.\u201d<\/em>\n      <\/p>\n<p align=\"both\">As part of this decision, Innate will immediately begin to reduce its US commercial operations; however, it will maintain the appropriate patient and customer support services, as well as product supply, during this transition period. In the EU, Innate will no longer progress Lumoxiti regulatory or commercial activities. \u00a0\u00a0<\/p>\n<p align=\"both\">The accounting impacts will be presented in the December 31, 2020 financial statements. As a reminder, the net book value of Lumoxiti intangible assets amounted to \u20ac45.2 million, as of June\u00a030, 2020.\u00a0\u00a0<\/p>\n<p align=\"left\">All other agreements with AstraZeneca remain unchanged.\u00a0<\/p>\n<p align=\"both\">\n        <strong>About <\/strong><br \/>\n        <strong>Lumoxiti (moxetumomab pasudotox-tdfk):<\/strong>\n      <\/p>\n<p align=\"both\">Lumoxiti is a CD22-directed immunotoxin and a first-in-class treatment in the US for adult patients with relapsed or refractory (r\/r) hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Lumoxiti is not recommended in patients with severe renal impairment (CrCl \u2264 29 mL\/min). It comprises the CD22 binding portion of an antibody fused to a truncated pseudomonas exotoxin. The toxin inhibits protein synthesis and ultimately triggers apoptotic cell death. Lumoxiti received U.S. FDA approval in September 2018 and has been granted Orphan Drug Designation by the FDA and the EMA for the treatment of r\/r HCL. AstraZeneca is the marketing authorization applicant for the EU filing.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:860px;text-align: center;vertical-align: middle;border-top: solid black 1pt;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <b><br \/>\n              <i>A conference call will be held today at 2:00pm CET (8:00am ET)<\/i><br \/>\n            <\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <a href=\"https:\/\/edge.media-server.com\/mmc\/p\/4mpdd99d\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <u>Webcast access: https:\/\/edge.media-server.com\/mmc\/p\/4mpdd99d\u00a0<\/u><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">or <b>Dial in numbers<\/b>:\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">France: +33 (0)1 70 70 07 81\u00a0\u00a0\u00a0\u00a0\u00a0 US only: + 1 877 870 9135<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">Standard International: +44 (0) 2071 928338<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">Conference ID: <b>9198932<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <b>\u00a0<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <i>The access to the live webcast will be available on Innate Pharma\u2019s website 30 minutes ahead of the conference.\u00a0<\/i>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center;vertical-align: middle;border-left: solid black 1pt;border-bottom: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <i>A replay will be available on Innate Pharma\u2019s website after the conference call.<\/i>\n          <\/td>\n<\/tr>\n<\/table>\n<p align=\"both\">\n<p align=\"both\">\n        <strong>About Innate Pharma:<br \/><\/strong>Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.<\/p>\n<p align=\"both\">Innate Pharma\u2019s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.<\/p>\n<p align=\"both\">Innate has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A\/S, Sanofi, and a multi-products collaboration with AstraZeneca.<\/p>\n<p align=\"both\">Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n<p align=\"both\">Learn more about Innate Pharma at www.innate-pharma.com<\/p>\n<p align=\"both\">\n        <strong>Information about Innate Pharma shares:<\/strong>\n      <\/p>\n<table align=\"center\" style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">\n            <strong>ISIN code<\/strong><br \/>\n            <br \/>\n            <strong>Ticker code<\/strong><br \/>\n            <br \/>\n            <strong>LEI<\/strong>\n          <\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: top\">FR0010331421<br \/>Euronext: IPH Nasdaq: IPHA<br \/>9695002Y8420ZB8HJE29<\/td>\n<\/tr>\n<\/table>\n<p align=\"both\">\n        <strong>Disclaimer on forward-looking information and risk factors<\/strong><br \/>\n        <strong>:<\/strong>\n      <\/p>\n<p align=\"both\">This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including \u201cbelieve,\u201d \u201cpotential,\u201d \u201cexpect\u201d and \u201cwill\u201d and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company\u2019s commercialization efforts, the Company\u2019s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company\u2019s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company&#8217;s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque&#8221;) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website http:\/\/www.amf-france.org or on Innate Pharma\u2019s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.<\/p>\n<p align=\"both\">This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n<p align=\"both\">\n        <strong>For additional information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong><br \/>\n              <u>Investors<\/u><br \/>\n            <\/strong><br \/>\n            <br \/>\n            <strong>Innate Pharma<\/strong><br \/>\n            <br \/>Tel.: +33 (0)4 30 30 30 30<br \/><a href=\"mailto:investors@innate-pharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@innate-pharma.com<\/a><\/p>\n<\/td>\n<td style=\"vertical-align: top\">\n            <strong><br \/>\n              <u>Media<\/u><br \/>\n            <\/strong><br \/>\n            <br \/>\n            <strong>Innate Pharma <\/strong><br \/>\n            <br \/>Tracy Rossin (Global\/US)<br \/>Tel.: +1 240 801 0076<br \/><a href=\"mailto:Tracy.Rossin@innate-pharma.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Tracy.Rossin@innate-pharma.com<\/a><\/p>\n<p><strong>ATCG Press<\/strong><br \/>Marie Puvieux (France)<br \/>Tel.: +33 (0)9 81 87 46 72<br \/><a href=\"mailto:innate-pharma@atcg-partners.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">innate-pharma@atcg-partners.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p align=\"both\">\n        <sup>1<\/sup> Lumoxiti is licensed from MedImmune, a subsidiary of AstraZeneca.<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e1f34a44-aad5-43c5-8979-a181134b6d75\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Innate will no longer pursue Lumoxiti commercialization activities in US or E U ; Company to re -focus investments in its R&amp;D p ortfolio\u00a0 Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021 C ompanies will ensure availability of Lumoxiti to patients during transition period C onference call to be held today at 2 pm CET \/ 8 am ET MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Innate Pharma SA (Euronext Paris: IPH \u2013 ISIN: FR0010331421; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1. Innate licensed the US and EU rights to AstraZeneca\u2019s FDA-approved &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-398020","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Innate will no longer pursue Lumoxiti commercialization activities in US or E U ; Company to re -focus investments in its R&amp;D p ortfolio\u00a0 Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021 C ompanies will ensure availability of Lumoxiti to patients during transition period C onference call to be held today at 2 pm CET \/ 8 am ET MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Innate Pharma SA (Euronext Paris: IPH \u2013 ISIN: FR0010331421; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1. Innate licensed the US and EU rights to AstraZeneca\u2019s FDA-approved &hellip; Continue reading &quot;Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T06:03:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca\",\"datePublished\":\"2020-12-11T06:03:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/\"},\"wordCount\":1087,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/\",\"name\":\"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=\",\"datePublished\":\"2020-12-11T06:03:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/","og_locale":"en_US","og_type":"article","og_title":"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca - Market Newsdesk","og_description":"Innate will no longer pursue Lumoxiti commercialization activities in US or E U ; Company to re -focus investments in its R&amp;D p ortfolio\u00a0 Companies will develop a transition plan with the goal of returning full commercialization responsibilities to AstraZeneca in 2021 C ompanies will ensure availability of Lumoxiti to patients during transition period C onference call to be held today at 2 pm CET \/ 8 am ET MARSEILLE, France, Dec. 11, 2020 (GLOBE NEWSWIRE) &#8212; Innate Pharma SA (Euronext Paris: IPH \u2013 ISIN: FR0010331421; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) today announced that it will return the US and EU commercialization rights of Lumoxiti (moxetumomab pasudotox-tdfk) to AstraZeneca1. Innate licensed the US and EU rights to AstraZeneca\u2019s FDA-approved &hellip; Continue reading \"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-11T06:03:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca","datePublished":"2020-12-11T06:03:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/"},"wordCount":1087,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/","name":"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=","datePublished":"2020-12-11T06:03:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEwMDUyOSMzODY2NzQ4IzEwMTE0NTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/innate-pharma-to-return-us-and-eu-lumoxiti-commercialization-rights-to-astrazeneca\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Innate Pharma to Return US and EU Lumoxiti Commercialization Rights to AstraZeneca"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=398020"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/398020\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=398020"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=398020"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=398020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}